Reportstack

Focal Segmental Glomerulosclerosis (FSGS) Pipeline Review, H2 2012 New Report

 

Naperville, IL -- (SBWIRE) -- 12/13/2012 -- Focal Segmental Glomerulosclerosis (FSGS) - Pipeline Review, H2 2012, provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Focal Segmental Glomerulosclerosis (FSGS), complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Focal Segmental Glomerulosclerosis (FSGS)

Scope

- A snapshot of the global therapeutic scenario for Focal Segmental Glomerulosclerosis (FSGS).
- A review of the Focal Segmental Glomerulosclerosis (FSGS) products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Focal Segmental Glomerulosclerosis (FSGS) pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Focal Segmental Glomerulosclerosis (FSGS).
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Focal Segmental Glomerulosclerosis (FSGS) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

To view table of contents for this market report please visit:
http://www.reportstack.com/product/91331/focal-segmental-glomerulosclerosis-fsgs-pipeline-review-h2-2012.html